McKesson Co. (NYSE:MCK) has received a consensus rating of “Hold” from the fifteen analysts that are presently covering the firm, MarketBeat.com reports. Two investment analysts have rated the stock with a sell rating, six have assigned a hold rating and six have assigned a buy rating to the company. The average 12 month price objective among analysts that have updated their coverage on the stock in the last year is $136.99.
A number of research firms have recently weighed in on MCK. ValuEngine upgraded McKesson from a “strong sell” rating to a “sell” rating in a report on Monday, October 29th. Morgan Stanley reduced their price objective on McKesson from $142.00 to $130.00 in a report on Sunday, December 9th. Royal Bank of Canada set a $155.00 target price on McKesson and gave the stock a “hold” rating in a research report on Friday, October 26th. Zacks Investment Research cut McKesson from a “hold” rating to a “sell” rating in a research note on Thursday, January 3rd. Finally, Barclays decreased their price objective on McKesson from $150.00 to $136.00 and set an “equal weight” rating for the company in a report on Friday, October 26th.
Several large investors have recently made changes to their positions in MCK. IMS Capital Management acquired a new position in shares of McKesson during the 3rd quarter worth approximately $57,000. Fort L.P. acquired a new position in shares of McKesson during the 2nd quarter worth approximately $110,000. Flagship Harbor Advisors LLC acquired a new position in shares of McKesson during the 2nd quarter worth approximately $118,000. Reilly Financial Advisors LLC grew its position in shares of McKesson by 506.8% during the 3rd quarter. Reilly Financial Advisors LLC now owns 898 shares of the company’s stock worth $119,000 after purchasing an additional 750 shares in the last quarter. Finally, Bray Capital Advisors acquired a new position in shares of McKesson during the 3rd quarter worth approximately $123,000. Hedge funds and other institutional investors own 85.31% of the company’s stock.
Shares of MCK stock traded down $0.42 on Friday, reaching $121.62. The company’s stock had a trading volume of 90,938 shares, compared to its average volume of 1,839,348. The company has a debt-to-equity ratio of 0.69, a quick ratio of 0.56 and a current ratio of 0.99. The firm has a market cap of $23.11 billion, a PE ratio of 9.66, a price-to-earnings-growth ratio of 1.35 and a beta of 1.06. McKesson has a 1 year low of $106.11 and a 1 year high of $178.86.
McKesson (NYSE:MCK) last announced its earnings results on Thursday, October 25th. The company reported $3.60 EPS for the quarter, topping the Zacks’ consensus estimate of $3.28 by $0.32. The business had revenue of $53.08 billion during the quarter, compared to the consensus estimate of $53.56 billion. McKesson had a net margin of 0.06% and a return on equity of 26.55%. On average, equities analysts predict that McKesson will post 13.41 EPS for the current year.
The business also recently declared a quarterly dividend, which was paid on Wednesday, January 2nd. Investors of record on Monday, December 3rd were paid a $0.39 dividend. The ex-dividend date of this dividend was Friday, November 30th. This represents a $1.56 dividend on an annualized basis and a yield of 1.28%. McKesson’s dividend payout ratio (DPR) is currently 12.36%.
McKesson Company Profile
McKesson Corporation provides pharmaceuticals and medical supplies in the United States and internationally. It operates in three segments: U.S. Pharmaceutical and Specialty Solutions, European Pharmaceutical Solutions, and Medical-Surgical Solutions. The company distributes branded, generic, specialty, biosimilar, and over-the-counter pharmaceutical drugs, as well as other healthcare-related products; and offers practice management, technology, clinical support, and business solutions to community-based oncology and other specialty practices.
Further Reading: Day Trading – Risk Worth the Reward?
Receive News & Ratings for McKesson Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for McKesson and related companies with MarketBeat.com's FREE daily email newsletter.